ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Diabetes"

  • Abstract Number: 2404 • 2016 ACR/ARHP Annual Meeting

    Prevalence of Subclinical Entheseal Involvement in Children and Adolescents with Type 1 Diabetes: A Case Control Study

    Alberto Batticciotto1, Andrea Scaramuzza2, Matteo Ferrari3, Maria Chiara Ditto4, Maria Chiara Gerardi4, Fabiola Atzeni1 and Piercarlo Sarzi-Puttini4, 1Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, 2Department of Pediatrics, University of Milan, Milano, Italy, 3Department of Pediatrics, University of Milan, Milan, Italy, 4Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy

    Background/Purpose: The clinical course of type one diabetes (T1D) is frequently complicated by musculoskeletal manifestations such as Dupuytren’s disease, trigger finger, shoulder adhesive capsulitis and…
  • Abstract Number: 3047 • 2016 ACR/ARHP Annual Meeting

    Diabetes and BMI Modify the Association Between Painful Hip OA and All-Cause Mortality

    Rebecca Cleveland1, Todd A. Schwartz2, Jordan B. Renner3, Leigh F. Callahan1 and Joanne M. Jordan1, 1Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Individuals with specific comorbid conditions have increased risk of having hip osteoarthritis (OA). Some of these conditions are also associated with increased risk of…
  • Abstract Number: 331 • 2015 ACR/ARHP Annual Meeting

    Are Metabolic Factors Associated with Shoulder Osteoarthritis? a Multicentric Study.

    Pierre-Antoine Juge1, Laure Bérard2, Salma Kotti3, Tabassome Simon4, Francis Berenbaum5, Geoffroy Nourissat6 and Jérémie Sellam7, 1Rheumatology Department, Saint-Antoine Hospital, Paris, France, 2Rheumatology Department, Le Havre Hospital, Le Havre, France, 3Unité de Recherche Clinique de l’Est Parisien, Saint-Antoine Hospital, Paris, France, 4Unité de Recherche Clinique de l'Est Parisien URCEST, Saint-Antoine Hospital, AP-HP, Univ Paris 06, Paris, France, 5Rheumatology, Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, 6Orthopedic surgery, Clinique des Maussins & St-Antoine Hospital AP-HP, Paris, France, 7Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France

    Background/Purpose: Aging, trauma and obesity are the 3 main risk factors for knee, hip and hand osteoarthritis (OA). It is noteworthy that risk factors for…
  • Abstract Number: 2243 • 2015 ACR/ARHP Annual Meeting

    Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey

    Robert Morlock1, Natalia M. Flores2, Kathy Annunziata3, Jonathan Chapnick4 and Javier Nuevo5, 14939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, 2Kantar Health, Foster City, CA, 3Kantar Health, Princeton, NJ, 4Kantar Health, Horsham, PA, 5AstraZeneca, Madrid, Spain, Madrid, Spain

    Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is caused by chronic high serum uric acid (sUA) levels (ie, hyperuricemia),…
  • Abstract Number: 2260 • 2015 ACR/ARHP Annual Meeting

    High Prevalence of Hypomagnesemia and Its Relation to BMI, Type 2 Diabetes, and Clinical Disease Measures in a VA Outpatient Rheumatology Clinic Population

    Nitika Ghattaura1, Caleb Murphy2 and Peter Valen2,3, 1Rheumatology, University of Minnesota Medical School, Minneapolis, MN, 2University of Minnesota Medical School, Minneapolis, MN, 3Rheumatology, Minneapolis VAMC, Minneapolis, MN

    Background/Purpose: Magnesium plays an essential role in multiple cellular reactions, and there is increasing interest in its role in inflammation and pain. It has been…
  • Abstract Number: 2737 • 2015 ACR/ARHP Annual Meeting

    Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program

    Jeffrey R. Curtis1, Ara Dikranian2, Alan Mendelsohn3, Koshika Soma4, Haiyun Fan3 and Chudy Nduaka3, 1University of Alabama at Birmingham, Birmingham, AL, 2San Diego Arthritis Medical Clinic, San Diego, CA, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often have comorbidities that may affect treatment response.…
  • Abstract Number: 3116 • 2015 ACR/ARHP Annual Meeting

    High Level of Inflammation Predicts the Development of Diabetes Mellitus in Patients with Psoriatic Arthritis

    Lihi Eder1, Vinod Chandran1, Richard J. Cook2 and Dafna D. Gladman1, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: To estimate trends in the prevalence of diabetes mellitus (DM) in patients with psoriatic arthritis (PsA) in comparison to the general population in Ontario,…
  • Abstract Number: 46 • 2014 ACR/ARHP Annual Meeting

    Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout

    Seoyoung C. Kim1, John D. Seeger2, Jun Liu3 and Daniel H. Solomon4, 1Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 3Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Hyperuricemia and gout are associated with an increased risk of type 2 diabetes (T2D). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the main…
  • Abstract Number: 2507 • 2014 ACR/ARHP Annual Meeting

    Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret®)?

    Barbara Missler-Karger1, Hans-Eckhard Langer2, Mika Leinonen3 and Björn Pilström4, 1Rheumatology consultant, Cologne, Germany, 2RHIO Research Institute, Düsseldorf, Germany, 34Pharma AB, Stockholm, Sweden, 4TA Inflammation, Swedish Orphan Biovitrum AB, Stockholm, Sweden

    Background/Purpose 458 patients with rheumatoid arthritis (RA) and inadequate response to traditional DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist…
  • Abstract Number: 2306 • 2014 ACR/ARHP Annual Meeting

    Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines

    Timothy J Schmidt1,2, J Antonio Avina-Zubieta2,3,4, Eric C. Sayre3, Michal Abrahamowicz5, John M. Esdaile2,6,7 and Diane Lacaille8,9,10, 1Arthritis Research Centre of Canada, Richmind, BC, Canada, 2Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, 3Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, 5Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, 6Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, 7Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, 8Arthritis Research Centre of Canada, Vancouver, BC, Canada, 9Medicine, University of British Columbia, Vancouver, BC, Canada, 10University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada

    Background/Purpose: Comorbidities are increasingly recognized as significant contributors of decreased quality of life, and increased mortality in RA. RA is associated with an increased risk…
  • Abstract Number: 1276 • 2014 ACR/ARHP Annual Meeting

    Hyperglycemia and Risk of Osteoarthritis

    Mona Walimbe1, Ann V. Schwartz2, Irina Tolstykh2, Charles E. McCulloch2, David T. Felson3, Cora E. Lewis4, Neil A. Segal5, Michael C. Nevitt2 and Nancy E. Lane6, 1Medicine, UCSF (University of California, San Francisco), San Francisco, CA, 2Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, 3Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 4Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, 5Orthopaedics and Rehabilitation, University of Iowa, Iowa City, IA, 6Internal Medicine, Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA

    Background/Purpose Osteoarthritis (OA) is reported to be more prevalent in individuals with diabetes mellitus (DM).  Potential etiologies include advanced glycation endproducts, which reduce cartilage integrity,…
  • Abstract Number: 1265 • 2014 ACR/ARHP Annual Meeting

    Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase

    Pari Basharat1, Arash Lahouti H.1, Andrew L. Mammen2, Iago Pinal-Fernandez1, Tanmayee Bichile3, Thomas E. Lloyd4, Sonye K. Danoff5, Livia Casciola-Rosen6 and Lisa Christopher-Stine7, 1Medicine, Johns Hopkins University, Baltimore, MD, 2Neurology and Medicine, Johns Hopkins University, Baltimore, MD, 3Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Neurology, Johns Hopkins, Baltimore, MD, 5Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, 6Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, 7Medicine and Neurology, Johns Hopkins University, Baltimore, MD

    Background/Purpose The idiopathic inflammatory myopathies (IIM) comprise a group of autoimmune disorders that target skeletal muscle. Some IIM cases may be associated with an autoantibody…
  • Abstract Number: 1113 • 2014 ACR/ARHP Annual Meeting

    Mayor Trocanter Painful Syndrome. Treatment with Hyaluronic Acid Versus Triamcinolone Acetonide Injections. a Comparative Study

    Asuncion Acosta Sr.1, Arturo Rodriguez de la Serna2, Berta Magallares2 and Gary Sterba Sr.3, 1Hospital Santa Creu i Sant Pau, Barcelona, Spain, 2Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 3rheumatology, rheumatologist, miami, FL

    Background/Purpose: Painful syndrome of the mayor trochanter(MTPS).The treatment includes intra-bursal injections with corticosteroids.Steroids.Estimate the efficacy of the treatment with hyaluronic acid injections in comparison to…
  • Abstract Number: 1064 • 2014 ACR/ARHP Annual Meeting

    Unique Profile of Cardiovascular Risk Factors in Rheumatoid Arthritis High-Risk Populations with Insufficient Risk Control

    Ulf Müller-Ladner1, Stefan Kleinert2, Klaus Krüger3, Bianca Wittig4 and Rolf Hecker4, 1Rheumatologie und klinische Immunologie, Kerckhoff-Klinik GmbH, Abt. Rheumatologie und klinische Immunologie, Bad Nauheim, Germany, 2Rheumatologie, Praxisgemeinschaft Rheumatologie-Nephrologie, Rheumatologische Schwerpunktpraxis, Erlangen, Germany, 3Praxiszentrum St. Bonifatius, München, Germany, 4Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany

    Background/Purpose More than 50% of premature deaths in patients with rheumatoid arthritis (RA) are due to cardiovascular disease (CVD). Both the cumulative burden of inflammation…
  • Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting

    Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus

    Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom

    Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology